RT Journal Article
SR Electronic
T1 IgG antibody seroconversion and the clinical progression of COVID-19 pneumonia: A retrospective, cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20154088
DO 10.1101/2020.07.16.20154088
A1 Kurashima, Kazuyoshi
A1 Kagiyama, Naho
A1 Ishiguro, Takashi
A1 Takaku, Yotaro
A1 Nakajima, Hiromi
A1 Shibata, Shun
A1 Matsui, Yuma
A1 Takano, Kenji
A1 Isono, Taisuke
A1 Nishida, Takashi
A1 Kawate, Eriko
A1 Hosoda, Chiaki
A1 Kobayashi, Yoichi
A1 Takayanagi, Noboru
A1 Yanagisawa, Tsutomu
YR 2020
UL http://medrxiv.org/content/early/2020/07/17/2020.07.16.20154088.abstract
AB Background Coronavirus Disease 2019 (COVID-19) causes severe acute respiratory failure. Antibody-dependent enhancement (ADE) is known as the mechanism for severe forms of other coronavirus diseases. The clinical progression of COVID-19 before and after IgG antibody seroconversion was investigated.Methods Fifty-three patients with reverse transcriptase PCR (RT-PCT)-confirmed COVID-19 viral pneumonia with or without respiratory failure were retrospectively investigated. The timing of the first IgG antibody against SARS-CoV-2-positive date, as well as changes of C-reactive protein (CRP) as an inflammatory marker and blood lymphocyte numbers, was assessed using serial preserved blood samples.Findings Ten patients recovered without oxygen therapy (mild/moderate group), 32 patients had hypoxemia and recovered with antiviral drugs (severe/non-ICU group), and 11 patients had severe respiratory failure and were treated in the ICU (6 of them died; critical/ICU group). The first IgG-positive date (day 0) was observed from 5 to 18 days from the onset of disease. At day 0, a CRP peak was observed in the severe and critical groups, whereas there was no synchronized CRP peak on day 0 in the mild/moderate group. In the severe/non-ICU group, the blood lymphocyte number increased (P=0.0007) and CRP decreased (P=0.0007) after day 0, whereas CRP did not decrease and the blood lymphocyte number further decreased (P=0.0370) in the critical/ICU group.Interpretation The respiratory failure due to COVID-19 viral pneumonia observed in week 2 may be related to an antibody-related mechanism rather than uncontrolled viral replication. In the critical form of COVID-19, inflammation was sustained after IgG seroconversion.Funding noneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding supported in the work presented.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethics committee of Saitama Cardiovascular and Respiratory Center (IRB No. 2019062).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.